1189477-66-4
1189477-66-4
Chemical Structure
Nilutamide-d6
- CAS No.: 1189477-66-4
- Formula:C12H4D6F3N3O4
- Molecular Weight:323.26
IUPAC Name: 5,5-bis(methyl-d3)-3-(4-nitro-3-(trifluoromethyl)phenyl)imidazolidine-2,4-dione
InChIKey: XWXYUMMDTVBTOU-WFGJKAKNSA-N
SMILES: O=C1N(C2=CC(C(F)(F)F)=C(C=C2)[N+]([O-])=O)C(NC1(C([2H])([2H])[2H])C([2H])([2H])[2H])=O
Biological Activity: Nilutamide-d6 (Nilandron-d6) is the deuterium labeled Nilutamide. Nilutamide (Nilandron) is a non-steroidal anti-androgen agent proposed in the research of metastatic prostatic carcinoma[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Nilutamide-d6 | 99.77% | Nilutamide-d6 (Nilandron-d6) is the deuterium labeled Nilutamide. Nilutamide (Nilandron) is a non-steroidal anti-androgen agent proposed in the research of metastatic prostatic carcinoma. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Nilutamide (Standard) | ≥98% | Nilutamide (Standard) is the analytical standard of Nilutamide. This product is intended for research and analytical applications. Nilutamide (Nilandron) is an orally active nonsteroidal androgen receptor antagonist with affinity for androgen receptors but not for progestogen, estrogen or glucocorticoid receptors. Nilutamide can be used to research prostate cancer. Nilutamide also has antischistosomal properties. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Nilutamide | 99.74% | Nilutamide (Nilandron) is an orally active nonsteroidal androgen receptor antagonist with affinity for androgen receptors but not for progestogen, estrogen or glucocorticoid receptors. Nilutamide can be used to research prostate cancer. Nilutamide also has antischistosomal properties. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
- [2]. Harris MG, et al. Nilutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer. Drugs Aging. 1993 Jan-Feb;3(1):9-25. [Content Brief]
